DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Kineret (Anakinra) - Published Studies

 
 



Kineret Related Published Studies

Well-designed clinical trials related to Kineret (Anakinra)

Treatment with Anakinra improves disposition index but not insulin sensitivity in nondiabetic subjects with the metabolic syndrome: a randomized, double-blind, placebo-controlled study. [2011.07]

A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). [2011.05]

Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study). [2010.05.15]

Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study. [2009.03.15]

Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study. [2009.02]

Anakinra for rheumatoid arthritis. [2009.01.21]

Safety of extended treatment with anakinra in patients with rheumatoid arthritis. [2006.08]

A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. [2004.09]

The safety of anakinra in high-risk patients with active rheumatoid arthritis: six-month observations of patients with comorbid conditions. [2004.06]

Effects of anakinra monotherapy on joint damage in patients with rheumatoid arthritis. Extension of a 24-week randomized, placebo-controlled trial. [2004.06]

Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. [2004.05]

Concomitant medication use in a large, international, multicenter, placebo controlled trial of anakinra, a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis. [2004.04]

Pharmacokinetics of anakinra in subjects with different levels of renal function. [2003.07]

Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial. [2003.04]

Interleukin 1 receptor antagonist anakinra improves functional status in patients with rheumatoid arthritis. [2003.02]

Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial. [2002.11]

Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. [2002.03]

Well-designed clinical trials possibly related to Kineret (Anakinra)

The effects of exercise withdrawal on mood and inflammatory cytokine responses in humans. [2011.07]

Circulating Dickkopf-1 is correlated with bone erosion and inflammation in rheumatoid arthritis. [2011.05]

Secondary failure to treatment with recombinant human IL-1 receptor antagonist in Chinese patients with rheumatoid arthritis. [2011.05]

IL-1beta receptor antagonist reduces inflammation in hemodialysis patients. [2011.03]

Interleukin 1 receptor antagonist is associated with changes in body composition during physiological GH substitution in patients with adult-onset growth hormone deficiency. [2011.01]

Modulation of cytokine and cytokine receptor/antagonist by treatment with doxycycline and tetracycline in patients with dengue fever. [2011]

Secondary failure to treatment with recombinant human IL-1 receptor antagonist in Chinese patients with rheumatoid arthritis. [2011]

The effect of cytochrome P2C19 and interleukin-1 polymorphisms on H. pylori eradication rate of 1-week triple therapy with omeprazole or rabeprazole, amoxycillin and clarithromycin in Chinese people. [2010.12]

Synovial tissue rank ligand expression and radiographic progression in rheumatoid arthritis: observations from a proof-of-concept randomized clinical trial of cytokine blockade. [2010.11]

[Effects of parecoxib sodium preemptive analgesia on perioperative cytokine responses and stress responses in patients undergoing ophthalmology surgery]. [2010.07.20]

Synovial tissue and serum biomarkers of disease activity, therapeutic response and radiographic progression: analysis of a proof-of-concept randomised clinical trial of cytokine blockade. [2010.04]

Treatment with the PPARgamma agonist rosiglitazone downregulates interleukin-1 receptor antagonist in individuals with metabolic syndrome. [2010.02]

Changes in serum and synovial fluid biomarkers after acute injury (NCT00332254). [2010]

The effect of perioperative intravenous lidocaine on postoperative pain and immune function. [2009.11]

Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. [2009.09]

IL-1 receptor antagonism and muscle gene expression in patients with type 2 diabetes. [2009.06]

Cytokine gene polymorphisms in egyptian cases with brain tumors. [2009.06]

Induction of serum soluble tumor necrosis factor receptor II (sTNF-RII) and interleukin-1 receptor antagonist (IL-1ra) by interferon beta-1b in patients with progressive multiple sclerosis. [2008.08]

Resistin in serum is associated with higher levels of IL-1Ra in post-menopausal women with rheumatoid arthritis. [2008.07]

Systemic expression of cytokine production in patients with severe pneumococcal pneumonia: effects of treatment with a beta-lactam versus a fluoroquinolone. [2008.07]

Autologous interleukin-1 receptor antagonist improves function and symptoms in osteoarthritis when compared to placebo in a prospective randomized controlled trial. [2008.04]

Duration and severity of symptoms and levels of plasma interleukin-1 receptor antagonist, soluble tumor necrosis factor receptor, and adhesion molecules in patients with common cold treated with zinc acetate. [2008.03.15]

Effect of weight loss on cytokine messenger RNA expression in peripheral blood mononuclear cells of obese subjects with the metabolic syndrome. [2008.02]

Biologics for the treatment of juvenile idiopathic arthritis: a systematic review and critical analysis of the evidence. [2008.01]

Inflammation a possible link between economical stress and coronary heart disease. [2008]

Can the interleukin-1 receptor antagonist (IL-1ra) be a marker of anti-inflammatory response to enteral immunonutrition in malnourished patients after pancreaticoduodenectomy? [2007.11.09]

Quercetin's influence on exercise-induced changes in plasma cytokines and muscle and leukocyte cytokine mRNA. [2007.11]

Efficacy of epidural perineural injections with autologous conditioned serum for lumbar radicular compression: an investigator-initiated, prospective, double-blind, reference-controlled study. [2007.08.01]

Efficacy of epidural perineural injections with autologous conditioned serum for lumbar radicular compression: an investigator-initiated, prospective, double-blind, reference-controlled study. [2007.08.01]

Biologics for the treatment of juvenile idiopathic arthritis: a systematic review and critical analysis of the evidence. [2007.06.15]

Effect of blockade of TNF-alpha and interleukin-1 action on bone resorption in early postmenopausal women. [2007.05]

Interleukin-1-receptor antagonist in type 2 diabetes mellitus. [2007.04.12]

Clinical, biochemical, and histologic effects of intra-articular administration of autologous conditioned serum in horses with experimentally induced osteoarthritis. [2007.03]

Association of low-grade inflammation with nephropathy in type 2 diabetic patients: role of elevated CRP-levels and 2 different gene-polymorphisms of proinflammatory cytokines. [2007.01]

Exhaustion is associated with low macrophage migration inhibitory factor expression in patients with coronary artery disease. [2007.01]

Targeting adenosine receptors in the treatment of allergic rhinitis: a randomized, double-blind, placebo-controlled study. [2007.01]

Effect of meloxicam on gingival crevicular fluid IL-1beta and IL1 receptor antagonist levels in subjects with chronic periodontitis, and its effects on clinical parameters. [2006.12]

Serum IL-6 and IL-1-ra with sequential organ failure assessment scores in septic patients receiving high-volume haemofiltration and continuous venovenous haemofiltration. [2006.10]

[Targeted anti-cytokine therapies for osteoarthritis] [2006.10]

Blood leukocyte mRNA expression for IL-10, IL-1Ra, and IL-8, but not IL-6, increases after exercise. [2006.09]

Effects of sevoflurane on cytokine balance in patients undergoing coronary artery bypass graft surgery. [2006.08]

Self-rated health and vital exhaustion, but not depression, is related to inflammation in women with coronary heart disease. [2005.11]

Evidence of a pharmacogenomic response to interleukin-l receptor antagonist in rheumatoid arthritis. [2005.09]

Safety study of intraarticular injection of interleukin 1 receptor antagonist in patients with painful knee osteoarthritis: a multicenter study. [2005.07]

Acute inflammation and negative mood: mediation by cytokine activation. [2005.07]

Inflammatory response in children after laparoscopic vs open Nissen fundoplication: randomized controlled trial. [2005.06]

Modulation of clinical expression of plaque-induced gingivitis: interleukin-1 gene cluster polymorphisms. [2005.01]

Methylprednisolone favourably alters plasma and urinary cytokine homeostasis and subclinical renal injury at cardiac surgery. [2004.07.21]

Supplementation with vitamins C and E inhibits the release of interleukin-6 from contracting human skeletal muscle. [2004.07.15]

Lefunomide in combination therapy. [2004.06]

The effect of intravenous quinaprilat on plasma cytokines and hemodynamic variables during cardiac surgery. [2004.02]

[IL-1Ra (recombinant human IL-1 receptor antagonist) in the treatment of rheumatoid arthritis: the efficacy] [2004.01]

Decreased interleukin-1 receptor antagonist response following moderate exercise in patients with colorectal carcinoma after primary treatment. [2004]

Biologic agents for the treatment of juvenile rheumatoid arthritis: current status. [2004]

Cytokines in periradicular lesions: the effect of linezolid treatment. [2003.10]

Interleukin-1beta and interleukin-1ra levels in nasal lavages during experimental rhinovirus infection in asthmatic and non-asthmatic subjects. [2003.10]

Effects of plaque, psychological stress and gender on crevicular Il-1beta and Il-1ra secretion. [2003.03]

Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation. [2002.11.15]

Prevention of inflammation-induced endothelial dysfunction: a novel vasculo-protective action of aspirin. [2002.06.04]

Serum levels of tumor necrosis factor-alpha, soluble intercellular adhesion molecule-1, soluble vascular cell adhesion molecule-1, and soluble interleukin-1 receptor antagonist in patients with thyroid eye disease undergoing treatment with somatostatin analogues. [2001.12]

Association of HLA-DR genotypes and IL-1ra gene polymorphism with treatment failure of budesonide and disease patterns in Crohn's disease. [2001.12]

Effects of sleep on endotoxin-induced host responses in healthy men. [2001.07]

Cytokine changes after a marathon race. [2001.07]

Effect of vitamin supplementation on cytokine response and on muscle damage after strenuous exercise. [2001.06]

Interleukin-1 receptor antagonist treatment of rheumatoid arthritis patients: radiologic progression and correlation of Genant/Sharp and Larsen scoring methods. [2001.04]

Treatment of rheumatoid arthritis patients with interleukin-1 receptor antagonist: radiologic assessment. [2001.04]

The safety and efficacy of interleukin-1 receptor antagonist in the treatment of rheumatoid arthritis. [2001.04]

The effects of treatment with interleukin-1 receptor antagonist on the inflamed synovial membrane in rheumatoid arthritis. [2001.01]

A randomized controlled trial of interleukin-1 receptor antagonist in a rabbit model of ascending infection in pregnancy. [2001]

Interleukin-1 receptor antagonist as an adjunct in the treatment of Haemophilus influenzae otitis media in the chinchilla. [2000.09]

Cytokines and bone loss in a 5-year longitudinal study--hormone replacement therapy suppresses serum soluble interleukin-6 receptor and increases interleukin-1-receptor antagonist: the Danish Osteoporosis Prevention Study. [2000.08]

A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. [2000.05]

Cytokine RNA levels in transiliac bone biopsies from healthy early postmenopausal women. [2000.02]

Inflammatory response after laparoscopic and conventional colorectal resections - results of a prospective randomized trial. [2000.01]

Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. [1999.08.01]

IL-1ra administration does not improve cardiac function in patients with severe sepsis. [1999.06]

Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. [1998.12]

Cytokine production in haemodiafiltration: a multicentre study. [1998.07]

Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis. [1998.07]

Pro- and anti-inflammatory cytokines in healthy volunteers fed various doses of fish oil for 1 year. [1997.12]

Modulation of cytokine release and neutrophil function by granulocyte colony-stimulating factor during endotoxemia in humans. [1997.08.15]

Pharmacodynamics of subcutaneous recombinant human interleukin-10 in healthy volunteers. [1997.08]

Unopposed interleukin-1 is necessary for increased plasma cytokine and eicosanoid levels to develop in severe sepsis. [1997.07]

Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. [1997.07]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012